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Hepatocytes can be sensitized to tumor necrosis fac-
tor (TNF)-a toxicity by repression of NF-kB activation or
inhibition of RNA synthesis. To determine whether both
forms of sensitization lead to TNF-a cytotoxicity by sim-
ilar mechanisms, TNF-a-induced cell death in RALA255-
10G hepatocytes was examined following infection with
an adenovirus, Ad5IkB, that blocks NF-kB activation or
following cotreatment with actinomycin D (ActD).
TNF-a treatment of Ad5IkB-infected cells resulted in
44% cell death within 6 h. ActD/TNF-a induced no death
within 6 h but did lead to 37% cell death by 24 h. In both
instances, cell death occurred by apoptosis and was as-
sociated with caspase activation, although caspase acti-
vation in ActD-sensitized cells was delayed. CrmA and
chemical caspase inhibitors blocked Ad5IkB/TNF-a-in-
duced cell death but did not inhibit ActD/TNF-a-induced
apoptosis. A Fas-associated protein with death domain
(FADD) dominant negative decreased Ad5IkB/TNF-a-
and ActD/TNF-a-induced cell death by 81 and 47%, re-
spectively. However, downstream events differed, since
Ad5IkB/TNF-a but not ActD/TNF-a treatment caused mi-
tochondrial cytochrome c release. These results suggest
that NF-kB inactivation and inhibition of RNA synthesis
sensitize RALA255-10G hepatocytes to TNF-a toxicity
through distinct cell death pathways that diverge below
the level of FADD. ActD-induced hepatocyte sensitiza-
tion to TNF-a cytotoxicity occurs through a FADD-de-
pendent, caspase-independent pathway of apoptosis.
Prominent among the varied physiological effects of the cy-
tokine tumor necrosis factor-a (TNF-a)1 is its ability to act as a
cytotoxin and induce apoptotic or necrotic cell death (1). Al-
though TNF-a cytotoxicity has been widely investigated in the
context of its potential as an antineoplastic agent, recent stud-
ies have demonstrated that TNF-a may also induce death in
cells in normal tissue undergoing injury or inflammation.
TNF-a toxicity is particularly important to the pathophysiology
of liver disease, and TNF-a has been implicated as a mediator
of hepatocyte death following injury from toxins, ischemia/
reperfusion, and hepatitis virus (for a review, see Ref. 2). In
toxin-induced liver injury, endogenously produced TNF-a in-
duces a significant proportion of the subsequent liver cell death
as evidenced by the ability of TNF-a neutralization to dramat-
ically reduce liver injury from toxins such as carbon tetrachlo-
ride (3), actinomycin D (ActD) (4), and ethanol (5). Hepatocytes
are normally resistant to TNF-a cytotoxicity (6, 7); therefore,
these toxins sensitize hepatocytes to cell death from TNF-a by
an as yet unknown mechanism. In vitro investigations into the
mechanisms of TNF-a cytotoxicity in nonhepatic cells have
demonstrated that binding of TNF-a to tumor necrosis factor
receptor 1 (TNFR-1) results in receptor trimerization and the
recruitment of a series of intracellular proteins (1). Initially,
TNFR-associated death domain protein binds to the TNFR-1.
TNFR-associated death domain protein then recruits TNFR-
associated factor 2, Fas-associated protein with death domain
(FADD), and receptor-interacting protein (1, 8). Binding of
TNFR-associated death domain protein and FADD to the
TNFR-1 leads to the recruitment, oligomerization, and activa-
tion of caspase-8 (8, 9). Activated caspase-8 subsequently ini-
tiates a proteolytic cascade involving other caspase family
members, ultimately leading to apoptosis (10, 11). Activation of
these downstream caspases may be amplified by factors re-
leased from mitochondria such as cytochrome c (12, 13). Alter-
native caspase-8-independent mechanisms by which TNF-a
receptor binding initiates downstream caspase activation may
also exist. Investigations have demonstrated a FADD-inde-
pendent pathway of TNF-a-induced caspase activation involv-
ing RAIDD (14). Despite their differences, these pathways all
ultimately transduce the TNF-a death signal through the ac-
tivation of caspases.
The resistance of nontransformed cells to TNF-a-induced
cytotoxicity is thought to depend on the ability of TNF-a sig-
naling to up-regulate a protective cellular gene(s). This conclu-
sion is based on the finding that inhibition of RNA synthesis by
ActD or of protein synthesis by cycloheximide sensitizes non-
hepatic cells (15) and hepatocytes (4, 7) to TNF-a-induced cell
death. Recent investigations have demonstrated that cellular
activation of the transcription factor NF-kB is critical for the
induction of resistance to TNF-a toxicity (16–19). Blocking
NF-kB activation in cultured hepatocytes (12, 20) or in the liver
in vivo (21), converts the hepatocellular TNF-a response from
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one of proliferation to one of apoptosis. These results have
suggested that toxins such as ActD or carbon tetrachloride may
sensitize hepatocytes to TNF-a toxicity by blocking up-regula-
tion of an NF-kB-dependent protective gene. However, because
of differences in the amount of cell death caused by these two
forms of TNF-a toxicity (7, 20), we hypothesized that ActD and
NF-kB inhibition sensitize hepatocytes to TNF-a-induced
death by different mechanisms. By contrasting the involve-
ment of caspases, FADD, and cytochrome c in these two forms
of sensitization to TNF-a-induced cytotoxicity, the present
studies demonstrate that two distinct TNF-a cell death path-
ways exist in hepatocytes.
EXPERIMENTAL PROCEDURES
Materials—All reagents were from Sigma unless otherwise
indicated.
Cells and Culture Conditions—The rat hepatocyte cell line
RALA255–10G (22) was cultured in Dulbecco’s modified Eagle’s me-
dium (Life Technologies, Inc.) supplemented with 4% fetal bovine se-
rum (HyClone, Logan, UT), 2 mM glutamine, and antibiotics (Life Tech-
nologies, Inc.). These cells are conditionally transformed with a
temperature-sensitive T antigen. At the permissive temperature of
33 °C, they express T antigen, remain undifferentiated, and proliferate.
Culture of the cells at the restrictive temperature of 37 °C suppresses T
antigen expression, markedly slows growth, and allows differentiated
hepatocyte gene expression (22). For these experiments, the cells were
cultured at 33 °C until confluent, trypsinized, and replated at 0.65 3
106 cells/dish on 35-mm plastic dishes (Falcon; Becton Dickinson, Lin-
coln Park, NJ). After 24 h, the medium was changed to Dulbecco’s
modified Eagle’s medium supplemented with 2% fetal bovine serum,
glutamine, antibiotics, and 1 mM dexamethasone, and the cells were
placed at 37 °C.
After 3 days of culture at 37 °C, cells receiving adenovirus were
infected with 2 3 109 particles of the appropriate virus/dish (;1 3 103
particles/cell or 5–10 plaque-forming units/cell). In the case of double
virus infections, dishes received 2 3 109 particles of each virus simul-
taneously. Additional Ad5LacZ control virus was added when necessary
to make the total viral load equal in each dish. Three hours later,
infected and uninfected cells received fresh serum-free medium con-
taining dexamethasone. Medium was supplemented with dexametha-
sone to optimize hepatocyte differentiation as described previously (22).
Twenty hours later, some cells were pretreated with ActD (15 ng/ml) for
30 min. Untreated, infected, and ActD-treated cells then received rat
recombinant TNF-a (R & D Systems, Minneapolis, MN; ED50 of 10–20
pg/ml as measured by cytotoxicity in the L-929 cell line) at a concen-
tration of 10 ng/ml.
To inhibit caspase activity, cells were pretreated for 1 h before the
addition of TNF-a with the following caspase inhibitors dissolved in
dimethyl sulfoxide: 50 mM N-[(indole-2-carbonlyl)alaninyl]-3-amino-
4-oxo-5-fluoropentanoic acid (IDN-1529) or N-[(1,3-dimethylindole-2-
carbonyl)-valinyl]-3-amino-4-oxo-5-fluoropentanoic acid (IDN-1965)
(IDUN Pharmaceuticals, La Jolla, CA), 100 mM Ac-Tyr-Val-Ala-Asp-
chloromethylketone, Ac-Asp-Glu-Val-Asp-aldehyde, and Val-Ala-Asp-
fluoromethylketone (BACHEM, Torrance, CA). IDN-1529 has broad
anti-caspase activity, inhibiting caspase-1, -3, -6, and -8, and IDN-1965
is a pancaspase inhibitor with some selectivity toward caspase-6 and
-8.2
Adenovirus Construction and Infection—The recombinant, replica-
tion-deficient adenovirus Ad5IkB was used as described previously to
inhibit NF-kB activation (20). This adenovirus contains an IkB con-
struct in which serines 32 and 36 are mutated to alanines, driven by the
cytomegalovirus promoter-enhancer. This mutant IkB cannot be phos-
phorylated and therefore irreversibly binds NF-kB, preventing its acti-
vation. In addition, the previously described viruses Ad5LacZ, which
contains the Escherichia coli b-galactosidase gene; a CrmA-expressing
adenovirus (12); and NFD-4, a dominant negative FADD adenovirus
(12), were employed. All viruses were grown in 293 cells and purified by
banding twice on CsCl gradients as described previously (20). Numbers
of viral particles were determined by optical densitometry, and recom-
binant virus was then stored in 25% (v/v) glycerol at 220 °C.
MTT Assay and Cell Counts—The amount of cell death was quanti-
fied from determinations of cell number with the 3-(4,5-dimethylthia-
zol-2-yl)-2,5 diphenyltetrazdium bromide (MTT) assay (23), as de-
scribed previously (20). The percentage of cell survival was calculated
by taking the optical density of cells given a particular treatment,
dividing that number by the optical density for the untreated, control
cells, and then multiplying by 100.
Alternatively, cell death was determined by doing manual counts of
the numbers of trypan blue-excluding cells following trypsinization.
The percentage of cell survival was calculated by taking the number of
trypan blue-excluding cells following treatment, dividing by the number
of untreated, control cells, and multiplying by 100.
Microscopic Determination of Apoptosis—Phase-contrast and fluores-
cent microscopy were conducted as described previously (24). The rel-
ative number of apoptotic cells was determined by fluorescent costain-
ing with acridine orange and ethidium bromide as previously employed
(20). The percentage of cells with apoptotic morphology (nuclear and
cytoplasmic condensation, nuclear fragmentation, membrane blebbing,
and apoptotic body formation) was determined by examining .400
cells/dish. Necrosis was determined by positive ethidium bromide stain-
ing. Fluorescent micrographs were taken on an Olympus IX microscope
with 3 40 long working distance infinity corrected optics.
Protein Isolation and Western Blot Analysis—To isolate protein for
caspase immunoblots, cells were scraped in medium and centrifuged.
The cell pellet was resuspended in lysis buffer containing 10 mM
HEPES (pH 7.4), 42 mM MgCl2, 1% Triton, 1 mM phenylmethylsulfonyl
fluoride, 1 mM EDTA, 1 mM dithiothreitol, and 2 mg/ml pepstatin A,
leupeptin, and aprotinin. The solution was then mixed at 4 °C for 30
min. After centrifugation, the supernatant was collected, and the pro-
tein concentration was determined by the Bio-Rad protein assay
(Bio-Rad).
Fifty micrograms of protein were heated in 13 SDS gel loading buffer
(50 mM Tris, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromphenol
blue, and 10% glycerol) at 100 °C for 2 min. The samples were subjected
to 10 or 12% SDS-PAGE and subsequently transferred to a nitrocellu-
lose membrane (Schleicher & Schuell) in transfer buffer containing 39
mM glycine, 48 mM Tris, pH 8.3, 0.037% SDS, and 15% methanol.
Membranes were stained with Ponceau Red to ensure equivalent
amounts of protein loading and electrophoretic transfer among sam-
ples. Blocking of the membranes was performed using a solution of 5%
nonfat milk, 10 mM Tris, pH 8.0, 0.15 M NaCl, and 0.05% Tween (TBS-T)
for 1 h. Rabbit anti-caspase-2 polyclonal IgG (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA), rabbit anti-caspase-3 polyclonal IgG, rabbit
anti-caspase-7 polyclonal IgG, or rabbit anti-caspase-8 polyclonal IgG
(IDUN Pharmaceuticals), were used as primary antibodies at 1:1000,
1:2000, 1:1000, and 1:2000 dilutions, respectively, in 5% milk-TBS-T for
2 h. A goat anti-rabbit IgG conjugated with horseradish peroxidase (Life
Technologies, Inc.) was used as a secondary antibody at a 1:10,000
dilution in 5% milk-TBS-T blocking solution for 1 h. Proteins were
visualized by chemiluminescence (Supersignal Ultra; Pierce).
For Western immunoblots of poly(ADP-ribose) polymerase (PARP),
centrifuged cells were suspended in lysis buffer composed of 20 mM Tris,
pH 7.5, 1% SDS, 2 mM EDTA, 2 mM EGTA, 6 mM b-mercaptoethanol,
and the protease inhibitors described above. After a 10-min incubation
on ice, cell suspensions were sonicated. Fifty micrograms of protein
were subjected to 8% SDS-PAGE as described above. Membranes were
exposed to rabbit anti-PARP polyclonal antibody (Santa Cruz Biotech-
nology) at a 1:4000 dilution followed by goat anti-rabbit secondary
antibody at a 1:20,000 dilution.
Quantification of DNA Hypoploidy by FACS—Identification of apo-
ptotic cells by detection of DNA loss after controlled extraction of low
molecular weight DNA was performed as described previously (25). At
various time points, cells were trypsinized, washed in Hanks’ buffered
saline solution, and pelleted. The cell pellets were resuspended and
fixed in 70% ethanol and stored at 220 °C for up to 1 week. After
washing twice in Hanks’ buffered saline solution, 1-ml Hanks’ buffered
saline solution cell suspensions were incubated with 0.5 ml of phos-
phate-citric acid buffer (0.2 M Na2HPO4, 0.1 M citric acid, pH 7.8) for 5
min to extract low molecular weight DNA from apoptotic cells. Subse-
quently, the cells were centrifuged, and the pellet was resuspended in
0.5 ml of Hanks’ buffered saline solution containing 20 mg/ml propidium
iodide and RNase (10 mg/ml). Following a 30-min incubation at room
temperature, cells were analyzed on a FACScan (Becton Dickinson
Immunocytometry Systems, San Jose, CA) at an excitation of 488 nm.
DNA fluorescence pulse processing was used to discriminate between
single cells and aggregates of cells (doublet discrimination) by evaluat-
ing the FL2-width versus FL2-area scatter plot. Light scatter gating
was used to eliminate smaller debris from analysis. DNA content was
displayed on a 4-decade logarithmic scale. An analysis gate was set to
limit the measurement of hypoploidy to an area of 10-fold loss of DNA
content (25).2 J. Wu, personal communication.
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Caspase-3-like Enzyme Activity Assay—Caspase-3-like enzyme activ-
ity was assayed in cells using a caspase-3 activity kit (BIOMOL, Plym-
outh Meeting, PA) according to the manufacturer’s instructions.
Mitochondrial Protein Isolation and Western Blots—Mitochondrial
fractions were prepared from RALA hepatocytes by differential centrif-
ugation in 250 mM sucrose buffer as described previously (26). Fifty
micrograms of mitochondrial protein were subjected to 15% SDS-PAGE
as described above. A mouse anti-cytochrome c monoclonal IgG (Pharm-
ingen, San Diego, CA) and a mouse anti-cytochrome oxidase subunit IV
monoclonal IgG (Molecular Probes, Inc., Eugene, OR) were used at
1:1000 dilutions together with a goat anti-mouse IgG conjugated to
horseradish peroxidase (Transduction Laboratories, Lexington, KY).
Statistical Analysis—All numerical results are reported as mean 6
S.E. and represent data from a minimum of three independent
experiments.
RESULTS
Sensitization to TNF-a Cytotoxicity Occurs More Rapidly
following NF-kB Inactivation than RNA Synthesis Inhibi-
tion—If NF-kB inactivation and RNA synthesis inhibition both
sensitize hepatocytes to TNF-a toxicity by blocking TNF-a-
inducible expression of a common protective gene(s), then the
timing of cell death should be similar after either form of
sensitization. The time course of TNF-a-induced cell death was
determined by MTT assay following inhibition of NF-kB acti-
vation by infection with the mutant-IkB-expressing adenovirus
Ad5IkB or inhibition of RNA synthesis by ActD. While TNF-a
alone was nontoxic to RALA hepatocytes, TNF-a treatment of
Ad5IkB-infected cells resulted in rapid hepatocyte death with a
44% decrease in cell number within only 6 h (Fig. 1), as previ-
ously established (20). By 24 h after TNF-a administration, cell
death further increased only slightly (Fig. 1). Infection of hepa-
tocytes with a control virus, Ad5LacZ, that expresses the b-ga-
lactosidase gene, failed to sensitize the cells to TNF-a toxicity
(data not shown). In contrast, TNF- a administration to hepa-
tocytes pretreated with ActD caused no cell death within 6 h
(Fig. 1). By 24 h, ActD/TNF-a treatment did result in 37% cell
death (Fig. 1). Pretreatment of cells with ActD at earlier time
points failed to alter the timing or amount of cell death follow-
ing TNF-a administration (data not shown).
To ensure that the MTT assay accurately represented the
numbers of cells surviving the various treatments, cell survival
was also determined by counts of trypan blue-excluding cells.
The amount of cell death as determined by this method (Table
I) was virtually identical to the MTT data (Fig. 1). These
results demonstrate that the time course of cell death after
TNF-a treatment differs markedly depending on the form of
sensitization, suggesting that NF-kB inactivation and RNA
synthesis inhibition may sensitize RALA hepatocytes to TNF-a
cytotoxicity by distinct mechanisms.
NF-kB Inactivation and ActD Both Sensitize RALA Hepato-
cytes to Death by Apoptosis—TNF-a-induced cell death is pre-
dominantly apoptotic but may also occur by necrosis. We have
previously established that TNF-a treatment following NF-kB
inactivation leads to hepatocyte apoptosis, with a marked in-
crease in the number of apoptotic cells occurring within 1–6 h
(20). To determine whether ActD/TNF-a-induced cell death
also occurred by apoptosis, cells were examined by fluorescent
microscopy after costaining with acridine orange and ethidium
bromide. In ActD/TNF-a-treated cells, no increase in the num-
ber of apoptotic cells occurred within 6 h after TNF-a treatment
(Fig. 2), consistent with the failure to detect any cell death at
this time point by MTT assay and cell counts. The percentage
of apoptotic cells did increase 2- and 4-fold by 8 and 12 h,
respectively, after ActD/TNF-a treatment (Fig. 2). ActD sensi-
tization did not induce necrosis, because the percentage of
necrotic cells as indicated by ethidium bromide positivity was
less than 1% in control and treated cells at the 6-, 8-, 12-, and
24-h time points. Although sensitization by ActD led to a de-
layed cell death relative to NF-kB inactivation, both forms of
sensitization caused TNF-a-induced death through apoptosis.
ActD/TNF-a-induced Apoptosis Is Associated with Caspase
Activation, PARP Cleavage, and DNA Hypoploidy—Most forms
of apoptosis are mediated by the proteolytic actions of caspases
(10). Previous studies have demonstrated that TNF-a treat-
ment of RALA hepatocytes sensitized by inhibition of NF-kB
activation resulted in caspase activation and PARP degrada-
tion (20). Caspase activation during ActD/TNF-a-induced
apoptosis was assessed by Western immunoblot analysis of
protein isolates from ActD/TNF-a-treated hepatocytes. Levels
of procaspase-2, -3, -7, and -8 were unchanged at 6 h following
ActD/TNF-a treatment, indicating that no caspase activation
had occurred by this time (Fig. 3). Significant caspase activa-
tion was also not detected at 8 and 12 h after ActD/TNF-a
treatment (data not shown). By 24 h, caspase activation had
occurred as demonstrated by the loss of procaspase-2, -7, and
-8, and the appearance of the processed subunits of caspase-3,
-7, and -8 (Fig. 3). Decreases in procaspase levels 24 h after
ActD/TNF-a treatment were much less than the dramatic de-
creases that occurred in Ad5IkB/TNF-a-treated cells at 6 h
(Fig. 3). No caspase activation occurred at 6, 8, 12, or 24 h in
cells treated with TNF-a alone (Fig. 3 and data not shown).
The immunoblot evidence of caspase activation in ActD/
TNF-a-treated cells at 24 h was substantiated by measure-
FIG. 1. Inhibition of NF-kB activation or RNA synthesis sensi-
tized RALA hepatocytes to TNF-a-induced cell death. Cells were
treated with TNF-a alone (TNF), infected with Ad5IkB and treated
with TNF-a (Ad5IkB/TNF), or treated with ActD and TNF-a (ActD/
TNF) as described under “Experimental Procedures.” The percentage of
survival was determined at 6, 8, 12, and 24 h relative to untreated
controls by MTT assay. Data are from three independent experiments,
each with duplicate dishes for every condition.
TABLE I
Cell survival following Ad5IkB/TNF-a or ActD/TNF-a treatment
without caspase inhibitor (A) or in the presence of IDN-1529 (11529)
Survival was determined by counts of trypan blue-excluding cells and
is expressed as a percentage of untreated control cells. Cells were
pretreated with the caspase inhibitor IDN-1529 1 h before the addition




A 11529 A 11529
h % %
6 56.3 6 1.6 86.8 6 4.7 100.0 6 4.7 ND
8 50.8 6 4.1 NDa 101.0 6 5.0 ND
12 51.0 6 3.5 ND 90.8 6 2.9 ND
24 40.2 6 2.7 66.3 6 3.5 62.0 6 3.4 58.8 6 1.4
a ND, not done.
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ments of caspase-3-like activity. At 8 h, no increase in activity
could be detected in ActD/TNF-a-treated cells (Fig. 4). How-
ever, at 24 h, a 2.7-fold increase in caspase-3-like-activity was
present in ActD/TNF-a-treated cells as compared with un-
treated control cells (Fig. 4).
To further ensure that the processed caspases were function-
ally active, ActD/TNF-a treated cells were examined for PARP
cleavage. No PARP cleavage could be detected at 6, 8, or 12 h
(data not shown), but PARP cleavage did occur within 24 h
after ActD/TNF-a treatment (Fig. 5). The appearance of PARP
cleavage therefore coincided with the timing of procaspase
processing by immunoblot analysis and the detection of
caspase-3-like activity.
DNA hypoploidy assays of hepatocytes stimulated by TNF-a
after sensitization with ActD were performed as an additional
biochemical marker of the presence and timing of caspase
activation and apoptosis. No significant increase in the propor-
tion of cells with reduced DNA content occurred at 8 h after
ActD/TNF-a administration (Fig. 6). By 24 h, a 4-fold increase
in the number of cells with DNA hypoploidy had occurred with
ActD/TNF-a treatment (Fig. 6). Caspase activation, PARP
cleavage, and DNA fragmentation all occurred after a similar
delay in ActD/TNF-a-treated cells.
Caspase Inhibition Prevents TNF-a-induced Apoptosis fol-
lowing NF-kB Inactivation but Not after ActD Treatment—To
determine whether activated caspases mediate TNF-a toxicity
in hepatocytes sensitized by either inhibition of NF-kB activa-
tion or RNA synthesis, the ability of CrmA and chemical
caspase inhibitors to prevent cell death was evaluated by MTT
assay. The viral caspase inhibitor CrmA was expressed in
RALA hepatocytes by an adenoviral vector. CrmA expression
reduced the amount of apoptosis in Ad5IkB/TNF-a-treated
cells by 52% at 6 h (Fig. 7). The chemical pancaspase inhibitors
IDN-1529 and IDN-1965 almost completely inhibited cell death
in Ad5IkB/TNF-a-treated hepatocytes (Fig. 7), similar to re-
sults previously published with lower doses of these inhibitors
(20). In contrast, apoptosis caused by ActD/TNF-a treatment
was not blocked by either CrmA expression or the addition of
the chemical caspase inhibitors IDN-1529 and IDN-1965 (Fig.
7). Counts of trypan blue-excluding cells confirmed that IDN-
1529 inhibited Ad5IkB/TNF-a-induced apoptosis but did not
block cell death from ActD/TNF-a (Table I). The additional
caspase inhibitors Ac-Tyr-Val-Ala-Asp-chloromethylketone
(100 mM), Ac-Asp-Glu-Val-Asp-aldehyde (100 mM), and Val-Ala-
Asp-fluoromethylketone (100 mM) also failed to prevent ActD/
TNF-a-induced apoptosis (data not shown). Cell death that
occurred in ActD/TNF-a-treated hepatocytes in the presence of
caspase inhibitors was apoptotic as indicated by the presence of
morphological features characteristic of apoptosis on fluores-
cent microscopy (Fig. 8). The percentage of apoptotic cells after
12 h of treatment with ActD/TNF-a (7.6 6 0.4%) was unaltered
FIG. 2. Time course of induction of apoptosis by TNF-a/ActD
treatment. RALA hepatocytes were untreated (Control) or treated
with ActD alone (ActD), and ActD combined with TNF-a (ActD/TNF).
The percentage of apoptotic cells was determined at 6, 8, and 12 h by
fluorescent costaining with acridine orange and ethidium bromide as
described under “Experimental Procedures.” Results are from three
independent experiments each with duplicate dishes for every data
point.
FIG. 3. Ad5IkB/TNF-a and ActD/TNF-a treatments induced
caspase activation. Aliquots of total cell lysates were subjected to
SDS-PAGE, and immunoblotting was performed using anti-caspase-2,
-3, -7, and -8 antibodies as described under “Experimental Procedures.”
Proteins was isolated from untreated cells, cells treated with TNF-a or
ActD/TNF-a, and Ad5IkB-infected cells with or without TNF-a at 6 and
24 h as indicated. Levels of procaspase-2, -3, -7, and -8 (indicated by pro)
along with the processed caspase-3, -7, and -8 subunits are shown.
FIG. 4. Caspase-3-like enzyme activity was increased by 24 h
after ActD/TNF-a treatment. Cells were untreated (Control) or were
treated with ActD/TNF-a alone (ActD/TNF) or together with IDN-1529
(ActD/TNF/1529). Caspase-3-like enzyme activity was determined at 8
and 24 h after TNF-a treatment. The changes in activity are shown
relative to control cell activity normalized to 100%. Results are from
three independent experiments with duplicate dishes for each point.
FIG. 5. TNF-a induced PARP cleavage in ActD/TNF-a-treated
cells at 24 h. RALA hepatocytes were treated with ActD/TNF-a alone
or together with the caspase inhibitor IDN-1529 for 24 h. Aliquots of
total cell lysates were subjected to SDS-PAGE, and immunoblotting
was performed with an anti-PARP antibody. The intact 116-kDa PARP
and its 85-kDa cleavage product are indicated.
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by the addition of IDN-1529 (7.2 6 0.6%). The percentage of
necrotic cells at 12 h (1.2 6 0.2%) was also unchanged by
IDN-1529 (1.0 6 0.1%). Caspase inhibition, therefore, did not
convert ActD/TNF-a-induced cell death from apoptosis to
necrosis.
To ensure that the failure of caspase inhibitors to block
ActD/TNF-a-induced apoptosis was not due to pharmacological
inactivity peculiar to this cell treatment, the effectiveness of
caspase inhibition was assessed in both models of sensitization.
Treatment of hepatocytes with IDN-1529 effectively blocked
the increases in caspase-3-like enzyme activity that occurred
after Ad5IkB/TNF-a or ActD/TNF-a treatment. In ActD/TNF-
a-treated cells, IDN-1529 prevented the rise in caspase-3-like
activity and even lowered activity 23 and 38% below levels in
untreated control cells at 8 and 24 h, respectively (Fig. 4).
Caspase inhibition also prevented PARP cleavage at 24 h (Fig.
5). Finally, the addition of this caspase inhibitor to ActD/TNF-
a-treated cultures completely abrogated internucleosomal
DNA cleavage as determined by FACS. Caspase inhibition
reduced the percentage of cells displaying a sub-G1 DNA con-
tent to levels below that seen in control cells (Fig. 6). Therefore,
the failure of caspase inhibition to prevent TNF-a-induced
apoptotic death in ActD-sensitized hepatocytes was not second-
ary to insufficient inhibition of caspase activity.
TNF-a Cytotoxicity following Inhibition of either NF-kB Ac-
tivation or RNA Synthesis Is FADD-dependent—Critical to the
initiation of the TNF-a death response is the binding of FADD
to the TNF-a receptor binding complex (1, 8), although FADD-
independent pathways have been reported (14). The ability of
ActD/TNF-a to trigger apoptosis independent of caspase acti-
vation suggested that this form of apoptosis may occur inde-
pendently of FADD as well. To determine whether FADD is
integral to the death pathways activated in Ad5IkB- and ActD-
sensitized hepatocytes following TNF-a stimulation, FADD
function was inhibited by an adenovirus expressing a dominant
negative FADD. Cell death in hepatocytes sensitized to TNF-a
toxicity by Ad5IkB and ActD was inhibited 81 and 47%, respec-
tively, by FADD dominant negative expression. These findings
indicate that ActD/TNF-a-induced apoptosis was at least par-
tially dependent on FADD, despite the fact that the resultant
cell death occurred by a caspase-independent mechanism.
Ad5IkB/TNF-a but Not ActD/TNF-a Treatment Causes Mi-
tochondrial Cytochrome c Release—Despite the common in-
volvement of FADD in both forms of sensitization to TNF-a
cytotoxicity, the time differential in caspase activation between
the two models suggested that other events upstream of
caspase activation must differ in the two types of sensitization.
Mitochondrial release of cytochrome c is a common mechanism
of caspase activation during apoptosis (27) and has been re-
FIG. 6. ActD/TNF-a treatment in-
duced caspase-dependent DNA deg-
radation at 24 h. Apoptosis was quanti-
tated by flow cytometric analysis of
propidium iodide-stained cells as de-
scribed under “Experimental Proce-
dures.” A, DNA histograms demonstrat-
ing the distribution of DNA content in
untreated cells (Control) and cells treated
with ActD/TNF-a alone (ActD/TNF) and
together with IDN-1529 (ActD/TNF/
1529) for 8 and 24 h. The percentage of
cells that contained sub-G1 amounts of
DNA in this representative experiment
are indicated. B, percentage of sub-G1
cells in control and in ActD/TNF-a- and
ActD/TNF-a/IDN-1529-treated cultures
after 8 and 24 h. Results are from three
independent experiments with duplicate
dishes for each data point.
FIG. 7. Caspase inhibition prevented cell death from treat-
ment with Ad5IkB/TNF-a but not ActD/TNF-a. Cells were infected
with an adenovirus expressing CrmA or pretreated with the caspase
inhibitors IDN-1529 and IDN-1965. Percentage of survival at 6 h
(Ad5IkB/TNF-a) or 24 h (ActD/TNF) was calculated relative to un-
treated controls by MTT assay. Data are from duplicate dishes in each
of three independent experiments.
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ported to occur in Ad5IkB/TNF-a-treated primary hepatocytes
(12). Mitochondrial loss of cytochrome c occurred in Ad5IkB/
TNF-a-treated RALA hepatocytes at 6 h (Fig. 9). In contrast, no
cytochrome c release resulted from ActD/TNF-a treatment at 6,
8, or even by 24 h (Fig. 9). To ensure that equal amounts of
mitochondrial protein had been isolated from each sample,
levels of cytochrome oxidase, a mitochondrial protein not re-
leased during apoptosis (28), were determined by Western blot
analysis and shown to be equivalent in all protein isolates (Fig.
9). This selective induction of mitochondrial cytochrome c re-
lease during Ad5IkB/TNF-a-induced but not ActD/TNF-a-in-
duced apoptosis further demonstrates that these two TNF-a
death pathways diverge below the level of FADD.
DISCUSSION
TNF-a has multiple biological effects on hepatocytes that
include either the stimulation of cellular proliferation or the
initiation of cell death. In rat liver, TNF-a induces both re-
sponses under different physiological circumstances, stimulat-
ing hepatocyte proliferation after partial hepatectomy (29, 30)
and inducing cell death during hepatotoxic injury (3). Our
previous investigations have demonstrated that hepatocyte
NF-kB activation is essential to preventing TNF-a cytotoxicity
(20), similar to findings in some nonhepatic cells (16–19). De-
spite the complex and diverse signaling cascades initiated by
TNF-a, inhibition of activation of the single transcription factor
NF-kB is sufficient to convert the TNF-a response from prolif-
eration to cell death both in cultured RALA hepatocytes (20)
and in hepatocytes in vivo following partial hepatectomy (21).
These results suggest that NF-kB is the transcriptional regu-
lator of a cellular gene(s) that when up-regulated by TNF-a
blocks the cellular death response to TNF-a and allows hepa-
tocellular proliferation to occur.
The concept that NF-kB up-regulates a protective cellular
gene is consistent with findings that inhibition of RNA or
protein synthesis sensitizes resistant cells including hepato-
cytes to cytotoxicity from TNF-a (4, 7, 15). Previous studies in
RALA hepatocytes demonstrated that ActD did not prevent
TNF-a-induced activation of NF-kB as measured by DNA bind-
ing activity, but ActD did partially inhibit NF-kB-dependent
gene expression (20). NF-kB inactivation or RNA/protein syn-
thesis inhibition may therefore act at different levels to ulti-
mately block expression of the same NF-kB-dependent cellular
gene. To examine this question, TNF-a-induced cell death in
RALA hepatocytes was compared following NF-kB inactivation
or ActD treatment. The present results indicate that the two
forms of TNF-a-induced cell death differ significantly in sev-
eral respects. The first difference is in the timing of cell death.
NF-kB inactivation resulted in immediate cell death with in-
creased numbers of apoptotic cells within only 1 h of TNF-a
treatment (20) and the majority of cell loss occurring in 6 h. In
contrast, ActD/TNF-a treatment led to a delayed induction of
cell death. No death occurred within 6 h after treatment, and a
small increase in the number of apoptotic cells was detected
only after 8 h of treatment. This disparate timing of cell death
in the two models suggests that the two forms of sensitization
activate distinct cell death pathways.
Despite the time differential, both forms of TNF-a toxicity
resulted in apoptotic cell death. Consistent with prior findings
that RALA hepatocyte death from Ad5IkB/TNF-a occurred by
apoptosis (20), ActD/TNF-a-induced cell death was also apo-
ptotic as determined by fluorescent microscopic studies, PARP
cleavage, and FACS analysis. All of these measures of apopto-
sis confirmed MTT and cell count data indicating that cell
death did not commence until 8 h after ActD/TNF-a treatment.
An additional hallmark of apoptosis in ActD/TNF-a-treated
cells was the presence of caspase activation. Western immuno-
blotting and caspase-3-like enzyme activity assays demon-
strated that caspase activation occurred following TNF-a stim-
ulation in cells sensitized by either Ad5IkB infection or ActD
treatment. In keeping with the divergent time courses of
apoptosis in the two models, caspase activation following ActD
sensitization occurred much later than that seen following
inhibition of NF-kB. Caspase activation was not evident until
24 h, in contrast to the rapid caspase activation previously
detected within 2 h after Ad5IkB/TNF-a treatment (20). Al-
though both models of TNF-a sensitization resulted in caspase
activation at times appropriate to the occurrence of apoptosis,
viral and chemical caspase inhibitors only blocked death in
Ad5IkB/TNF-a-treated cells. The failure of caspase inhibitors
to prevent ActD/TNF-a-induced apoptosis was not because of
insufficient caspase inhibition, because the chemical inhibitor
IDN-1529 markedly suppressed caspase-3-like activity in these
cells and completely abrogated the degradation of cellular
DNA. These data are consistent with reports of a caspase-
FIG. 8. ActD/TNF-a-induced cell death occurred by apoptosis despite the presence of a caspase inhibitor. Fluorescent micrographs
are from acridine orange-stained untreated cells (control), and cells treated for 24 h with ActD/TNF-a alone (Act/TNF) or together with
pretreatment with IDN-1529 (Act/TNF/1529). In the absence or presence of caspase inhibitor, ActD/TNF-a-treated cells underwent apoptosis as
indicated by numerous shrunken cells with condensed and fragmented chromatin.
FIG. 9. Mitochondrial cytochrome c release occurred with
Ad5IkB/TNF-a but not ActD/TNF-a treatment. Mitochondrial frac-
tions were prepared from untreated cells, cells treated with ActD/
TNF-a, and Ad5IkB-infected cells with or without TNF-a as indicated
at 6 and 24 h. Aliquots of mitochondrial lysates were subjected to
SDS-PAGE and immunoblotting performed with anti-cytochrome c
(Cyt. c) and anti-cytochrome oxidase (Cyt. ox.) antibodies.
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activated DNAase responsible for DNA fragmentation in apo-
ptosis (31) and the fact that DNA fragmentation is a late
phenomenon not essential for the occurrence of apoptotic cell
death (32).
RALA hepatocytes still exhibited morphological features of
apoptosis on fluorescent microscopy despite effective caspase
inhibition. The dissociation between the caspase-dependent
apoptotic parameters of PARP and internucleosomal DNA
cleavage and the caspase-independent morphological changes
demonstrated in the present study are consistent with recent
reports identifying the ability of a caspase-independent factor
to induce an apoptotic nuclear morphology (33, 34). Although
caspase activation occurred with ActD/TNF-a treatment and
was associated with caspase-dependent biochemical hallmarks
of apoptosis, caspase activation did not mediate apoptosis from
ActD/TNF-a treatment. Results in ActD/TNF-a-treated cells
are in marked contrast to those in Ad5IkB/TNF-a-treated cells
in which caspase activation was critical to the induction of
apoptosis. These data demonstrate that NF-kB inactivation
and ActD sensitize RALA hepatocytes to TNF-a cytotoxicity by
distinct mechanisms. In the absence of NF-kB, a critical inhib-
itor of the TNFR-1-triggered caspase cascade may not be up-
regulated, leading to a rapid caspase activation that commits
the cell to apoptosis. ActD sensitized hepatocytes to TNF-a-
induced death by a slower, and as yet undetermined mecha-
nism in which caspase activation was not critical for the com-
mitment to cell death. To our knowledge, these findings
represent the first report of TNF-a-induced apoptosis occurring
by a caspase-independent mechanism and add to the other
recent examples of caspase-independent apoptosis (32, 35).
These results differ from a recent report by Li et al. (36), who
demonstrated that in primary rat hepatocyte cultures ActD/
TNF-a caused a rapid, caspase-dependent apoptosis associated
with cytochrome c release. A potential explanation for these
divergent findings is that Li et al. employed a much higher
ActD concentration (200 ng/ml), which by itself causes a signif-
icant amount of hepatocyte apoptosis. Unlike our lower ActD
dose, their concentration may have more effectively inhibited
NF-kB-dependent gene transcription, making their model
equivalent to our Ad5IkB/TNF-a treatment. In addition, che-
motherapeutic drugs that interfere with macromolecular syn-
thesis induce apoptosis through the Fas death pathway (37,
38), and high dose ActD may also activate this caspase-depend-
ent pathway in hepatocytes. Alternatively, primary hepatocyte
cultures exist in a nonproliferative, proapoptotic state that may
alter cell death responses as compared with RALA hepatocytes
or hepatocytes in vivo.
To determine the level at which the two TNF-a death path-
ways diverge in RALA hepatocytes, the function of the TNFR-
1-binding protein FADD was blocked. Expression of a domi-
nant negative FADD significantly reduced cell death following
either Ad5IkB/TNF-a or ActD/TNF-a treatment, indicating
that these pathways diverge below the level of FADD. These
data demonstrate that in RALA hepatocytes FADD can trans-
duce the TNF-a death signal via a caspase-independent path-
way, in addition to the pathway involving caspase-8 activation
previously described in nonhepatic cells (9). This finding, to-
gether with the recent demonstration of FADD-dependent,
caspase-independent induction of necrosis in Jurkat cells by
Fas ligand (39), points to the ability of FADD to initiate cell
death through caspase-independent mechanisms. Subsequent
to the engagement of FADD, the two pathways of TNF-a-
induced cell death in hepatocytes diverge, with mitochondrial
cytochrome c release occurring with Ad5IkB/TNF-a- but not
ActD/TNF-a-induced apoptosis. Mitochondrial release of cyto-
chrome c is not essential for many forms of death receptor-
induced apoptosis but has been proposed to serve as an accel-
erator of this process (40). Receptor-mediated apoptosis has
been demonstrated to result from cytochrome c-independent
caspase activation through the direct actions of autoactivated
caspase-8 on caspase-3 and -7 (40). In RALA hepatocytes, cy-
tochrome c release may be required for the induction of a rapid,
caspase-dependent apoptotic pathway. In the absence of cyto-
chrome c release, the engagement of FADD triggers an alter-
native, caspase-independent death pathway. In nonhepatic
cells, FADD mediates activation of acid sphingomyelinase,
leading to ceramide generation (41). We have previously dem-
onstrated that RALA hepatocytes sensitized to ceramide toxic-
ity by ActD undergo caspase-independent apoptosis (42). It is
therefore possible that FADD-dependent ceramide signaling
induces cell death in ActD/TNF-a-treated RALA hepatocytes.
Cell death may occur from mitochondrial damage with result-
ant toxic generation of reactive oxygen species and depletion of
ATP. Further studies must now identify both the mechanism of
this caspase-independent death and the factors that regulate
whether sensitized hepatocytes enter a rapid, caspase-depend-
ent or slower, caspase-independent pathway of TNF-a-induced
apoptosis.
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